Advertisement

Breast Cancer Research and Treatment

, Volume 109, Issue 2, pp 359–365 | Cite as

Prevalence and prognostic and predictive relevance of PRAME in breast cancer

  • Padraig Doolan
  • Martin Clynes
  • Susan Kennedy
  • Jai Prakash Mehta
  • John Crown
  • Lorraine O’Driscoll
Epidemiology

Abstract

Preferentially expressed antigen of melanoma (PRAME) has been described as a potential candidate for immunotherapeutic targeting. However, the prognostic and predictive relevance of PRAME in breast cancer has never been investigated. PRAME gene expression was evaluated in 103 breast tumour biopsies, using quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). Normal breast tissue was also analysed for comparative purposes. All qRT-PCRs were performed in triplicate. Kaplan–Meier survival curves, Chi-squared and Cox Regression analyses were used to identify associations between PRAME expression and patients’ clinicopathological and survival data. PRAME mRNA was detected in ∼53% of tumour specimens and 37% of normal breast specimens. Kaplan–Meier analysis showed expression of PRAME to correlate significantly with unfavourable disease outcome for patients, in terms of both their disease-free survival (p = 0.0004) and overall survival (OS) (p = 0.0052) times from diagnosis. Multivariate analysis indicated PRAME expression to be an independent prognostic factor for shortened disease-free survival (p = 0.026) and OS (p = 0.02). Furthermore, for patients who received adjuvant chemotherapy, significantly (p = 0.0291) shorter relapse-free survival was achieved for those whose tumour expressed PRAME, compared to those that did not express this transcript. Our results suggest that PRAME mRNA expression may be a useful prognostic and predictive marker for breast cancer.

Keywords

Breast cancer PRAME Disease/relapse-free survival Overall survival Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) 

Notes

Acknowledgements

This work was supported by funding from Ireland’s Higher Educational Authority Programme for Research in Third Level Institutions (PRTLI) Cycle 3, Dublin City University’s Albert College Fellowship, Dublin City University’s Research Fellowship and the Health Research Board.

References

  1. 1.
    Ikeda H, Lethe B, Lehmann F et al (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199–208PubMedCrossRefGoogle Scholar
  2. 2.
    Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R (2005) The human tumour antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122:835–847PubMedCrossRefGoogle Scholar
  3. 3.
    Epping MT, Bernards R (2006) A causal role for the human tumour antigen preferentially expressed antigen of melanoma in cancer. Cancer Res 66:10639–10642PubMedCrossRefGoogle Scholar
  4. 4.
    Neumann E, Engelsberg A, Decker J et al (1998) Heterogeneous expression of the tumour-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res 58:4090–4095PubMedGoogle Scholar
  5. 5.
    Li CM, Guo M, Borczuk A et al (2002) Gene expression in Wilms’ tumour mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 160:2181–2190PubMedGoogle Scholar
  6. 6.
    Matsushita M, Yamazaki R, Kawakami Y (2004) Quantitative analysis of PRAME for detection of minimal residual disease in leukaemia. Methods Mol Med 97:267–275PubMedGoogle Scholar
  7. 7.
    Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M (2004) The tumour-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 10:4307–4313PubMedCrossRefGoogle Scholar
  8. 8.
    Proto-Siqueira R, Figueiredo-Pontes LL, Panepucci RA et al (2006) PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res 30:1333–1339PubMedCrossRefGoogle Scholar
  9. 9.
    Page DL, Andersen AT (1987) Diagnostic histopathology. Churchill Livingstone, London, Melbourne and New YorkGoogle Scholar
  10. 10.
    Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 403–410Google Scholar
  11. 11.
    Sobin LH, Wittekind C (1997) TNM Classification of Malignant tumours. Wiley, New YorkGoogle Scholar
  12. 12.
    Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T). Methods 25:402–408PubMedCrossRefGoogle Scholar
  13. 13.
    van Baren N, Chambost H, Ferrant A et al (1998) PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 102:1376–1379PubMedCrossRefGoogle Scholar
  14. 14.
    Watari K, Tojo A, Nagamura-Inoue T et al (2000) Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene. FEBS Lett 466:367–371PubMedCrossRefGoogle Scholar
  15. 15.
    McElwaine S, Mulligan C, Groet J et al (2004) Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down’s syndrome, revealing PRAME as a specific discriminating marker. Br J Haematol 125:729–742PubMedCrossRefGoogle Scholar
  16. 16.
    Paydas S, Tanriverdi K, Yavuz S, Disel U, Baslamisli F, Burgut R (2005) PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol 79:257–261PubMedCrossRefGoogle Scholar
  17. 17.
    Tajeddine N, Millard I, Gailly P, Gala JL (2006) Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. Clin Chem Lab Med 44:548–555PubMedCrossRefGoogle Scholar
  18. 18.
    Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B (2002) Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 133:118–123PubMedCrossRefGoogle Scholar
  19. 19.
    Steinbach D, Viehmann S, Zintl F, Gruhn B (2002) PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet 138:89–91PubMedCrossRefGoogle Scholar
  20. 20.
    van Baren N, Brasseur F, Godelaine D et al (1999) Genes encoding tumour-specific antigens are expressed in human myeloma cells. Blood 94:1156–1164PubMedGoogle Scholar
  21. 21.
    Matsushita M, Ikeda H, Kizaki M et al (2001) Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol 112:916–926PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Padraig Doolan
    • 1
  • Martin Clynes
    • 1
  • Susan Kennedy
    • 2
  • Jai Prakash Mehta
    • 1
  • John Crown
    • 1
    • 2
  • Lorraine O’Driscoll
    • 1
  1. 1.National Institute for Cellular BiotechnologyDublin City UniversityDublinIreland
  2. 2.St. Vincent’s University HospitalDublinIreland

Personalised recommendations